Oracle Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGEN
Agenus
AGEN
|
+$8.28M |
| 2 |
QuidelOrtho
QDEL
|
+$3.96M |
| 3 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$1.83M |
| 4 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$732K |
| 5 |
Pacific Biosciences
PACB
|
+$449K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$56.3M |
| 2 |
DERM
Dermira, Inc.
DERM
|
+$38.3M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$2.4M |
| 4 |
Cencora
COR
|
+$2.13M |
| 5 |
AXDX
Accelerate Diagnostics
AXDX
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.77% |
| 2 | Miscellaneous | 1.23% |
| 3 | Financials | 0% |
Similar funds
Oracle Investment Management's Q1 2020 Portfolio in Review
As of Q1 2020, Oracle Investment Management held 22 positions worth $337M, down 37% from $533M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Oracle Investment Management withdrew a net $85.7M in Q1 2020, closing 3 positions and reducing 7 holdings. Its most notable exit was Dermira, Inc., an estimated $38.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Oracle Investment Management opened a new position in Y-mAbs Therapeutics worth $658K.
- Oracle Investment Management's largest Q1 2020 buy was Y-mAbs Therapeutics: 25,212 shares worth $658K.
- Oracle Investment Management added most to Agenus in Q1 2020, an estimated $8.28M increase.
- Oracle Investment Management's biggest Q1 2020 reduction was Amarin Corp, cutting an estimated $56.3M.
- Oracle Investment Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $38.3M.
- Oracle Investment Management's ten largest holdings make up 97% of its $337M portfolio in Q1 2020.
- Oracle Investment Management opened 2 new positions and closed 3 in Q1 2020.
- Oracle Investment Management's portfolio value fell 37% quarter-over-quarter to $337M.
Based on Oracle Investment Management's 13F filing for Q1 2020, filed 15 May 2020.